Overview

PGT screens embryos for chromosomal abnormalities or specific genetic diseases before uterine transfer. By selecting only genetically healthy embryos, PGT aims to improve pregnancy rates, reduce miscarriage, and prevent births affected by serious conditions. Particularly relevant in the GCC, where consanguineous marriages increase the risk of autosomal recessive conditions like sickle cell disease and thalassaemia.

Types

• PGT-A — screens all 24 chromosomes for aneuploidy; most widely used; for advanced maternal age, recurrent miscarriage, or repeated IVF failure
• PGT-M — screens for a specific known genetic condition (sickle cell, thalassaemia, cystic fibrosis, BRCA, SMA); requires bespoke preparation per couple
• PGT-SR — for couples carrying chromosomal structural rearrangements

The PGT Process

1. IVF with ICSI to create embryos
2. Embryos cultured to blastocyst (day 5–6)
3. Trophectoderm biopsy — 5–10 cells from outer layer (not the inner cell mass)
4. Embryos vitrified while awaiting results (1–2 weeks)
5. Only passing embryos selected for frozen embryo transfer

Benefits & Limitations

• Higher implantation and ongoing pregnancy rates per transfer
• Reduced miscarriage rates
• Prevention of births with specific serious conditions (PGT-M)
• PGT-A does not guarantee pregnancy — a euploid embryo does not always implant
• Mosaic embryos require specialist counselling
• PGT-M needs 6–8 weeks advance preparation

Considering PGT? Book a consultation today